



Author Index for Volume 23

- Abrams, DI, 198
ADAPT Research Group, 93
Ahern, SP, 534
Alderman, EL, 708
Alonso, A, 607
Altimari, BR, 289
American Lung Association Asthma Clinical Research Centers, 87
AVID Coordinators and Investigators, 521
Avorn, J, 757

Babiker, A, 106
Baessler, C, 521
Ballard, DJ, 554
Barnes, CS, 554
Barofsky, I, 708
Barreto, ML, 540
Baseman, JB, 333
Bassford, T, 289
Bebchuk, JD, 59
Beckner, SK, 537
Bellissant, E, 423
Bender, R, 101
Benner, J, 757
Berger, VW, 502
Bethel, J, 536
Bittner, V, 708
Blackwelder, WC, 52
Bluhmki, E, 127
Boardman, KD, 333
Bogaerts, Kris, 127
Botto, A, 143
Branch, WT Jr, 554
Braun, TM, 240
Braveman, N, 301
Breitner, JCS, 93
Brenneman, T, 157
Brophy, M, 222
Buller, DB, 289
Buring, JE, 686
Burzykowski, T, 607
Buxbaum, J, 222
Buyse, M, 607

Caan, BJ, 728
Campbell, MK, 662
Castro-Caldas, A, 301
Chambliss, HO, 584
Chapman, PB, 367
Charleston, JB, 157
Chevret, S, 650
Chinchilli, VM, 426
Chow, S-C, 515
Clark, CG, 584
Clauw, DJ, 178, 184
Cobb, FR, 708
Cockcroft, J, 222
Collins, JF, 333
Cook, CB, 554
Cooper, DA, 198
Cotton, PB, 570
Cox, DR, 222
Crowley, JJ, 675
Cunha, SS, 540

Darbyshire, JH, 106, 198
de Brito, SC, 540
DeRouen, TA, 301
Dever, LL, 333
Devereaux, PJ, 380
Donovan, JL, 321
Donta, ST, 178, 184, 333
Dourado, I, 540
Doyle, JP, 554
DPP Research Group, The, 157
Dunn, AL, 584
Dunn, D, 106
Durkalski, VL, 570

Eberly, S, 635
Edelstein, C, 80
Edelstein, SL, 157
Egger, M, 321
El-Kebbi, IM, 554
Emery, S, 198
Engel, CC, Jr, 178, 184, 333
Enright, PL, 143
ESPRIT Study Group, 59, 198

Faerber, S, 728

Feng, Z, 431
Feussner, JR, 178, 184, 333
Fiore, L, 222
Fisher, EB, 157
Flatt, SW, 728
Ford, I, 757
Foreman, L, 521
Freidlin, B, 355
Fujimoto, WY, 157

Galbraith, S, 257
Gallina, DL, 554
Ganz, DA, 757
Gaw, A, 757
Gaziano, JM, 686
Gerald, LB, 87
Geys, H, 607
Ghali, WA, 380
Ghosh, D, 299
Gilpin, EA, 728
Glynn, RJ, 686, 757
Gold, EB, 728
Gönen, M, 367
Goodman, GE, 80
Goodman, PJ, 675
Gordon, DJ, 708
Gower, KB, 675
Greely, HT, 222
Greenberg, H, 222
Guarino, P, 178, 184
Guyatt, GH, 380

Haan, M, 728
Hall, RA, 289
Hall, WJ, 635
Hallstrom, A, 521
Halpern, SD, 274
Hannah, ME, 67
Harvey, IM, 321
Harvey, RF, 321
Hayes, RP, 554
Hennekens, CH, 686
Hertzberg, VS, 554
Hewson, SA, 67
Heywood, G, 521
Higginson, L, 708
Hijjar, MA, 540
Hilton, A, 74

- Holbrook, JT, 87
 Hollenbach, KA, 728
 Holmes, EW, 222
 Hooker, M, 106
 Howard, BV, 708
 Hsia, J, 708
 Hughes, MD, 703
 Hung, HMJ, 15
- Ichihara, MY, 540
 Ivanova, A, 183
- Jackson, J, 757
 Jones, L, 728
 Jones, VE, 728
 Jordan, R, 157
- Kampert, JB, 584
 Karim, MR, 389
 Kealey, S, 728
 Keinonen, T, 42
 Kessels, F, 74
 Knowler, WC, 157
 Kodama, Y, 29
 Koop, A, 469
 Korn, EL, 355
 Krause-Steinrauf, H, 222
 Kuselman, SJ, 426
- Lagaay, AM, 757
 Lakatos, E, 182
 Lane, HC, 198
 Lane, JA, 321
 Larkey, LK, 289
 Lavori, PW, 222
 Leitão, J, 301
 Leroux, BG, 301
 Lesaffre, E, 127
 Lévy, V, 650
 Li, N, 429
 Li, X, 127
 Lichterman, LC, 157
 Lin, H-M, 497
 Lodder, J, 74
 Lu, S, 143
 Lundgren, JD, 198
 Lyles, RH, 497, 554
- Malmstrom, K, 143
 Manns, BJ, 380
 Marrero, DG, 157
 Marschner, IC, 257
 Marshall, JR, 728
 Martin, BK, 93
 Martin, MD, 301
 Martin, SE, 333
 McClellan, WM, 554
- McDermott, CM, 59
 McDermott, MP, 635
 McEntegart, D, 424
 McNay, LA, 59
 McPherson, GC, 662
 Meinert, CL, 93
 Merz, JF, 172
 Miettinen, P, 42
 Miller, CD, 554
 Molenberghs, G, 607
 Mollerup, D, 59
 Morris, M, 521
 Mösges, R, 469
 Murray, LJ, 321
- Nagao, T, 29
 Nair, P, 321
 Natarajan, L, 728
 Neaton, JD, 58, 198
 Nelson, LM, 222
 Newman, V, 728
 Ng, ES-W, 409
 Nieminen, S, 42
- Oakes, D, 635
 Omenn, GS, 80
 Ono, S, 29
 Oseekey, K, 59
 Outcomes Research Working Group, 757
 Ouyang, P, 708
- Palesch, YY, 570
 Panageas, KS, 367
 Panzarella, T, 481
 Pauler, DK, 675
 Peduzzi, P, 178, 184
 Pereira, S, 540
 Perry, BH, 389
 Peszek, I, 143
 Phillips, LS, 554
 Pierce, JP, 728
 Pineau, BC, 570
 Porcher, R, 650
 Powell, J, 521
 Prince, M, 157
 Proschan, M, 708
 PROSPER Study Group, 757
 Putt, ME, 111
- Quan, H, 380
- Ramsay, CR, 662
 Ravina, B, 111
 Reiss, TF, 143
 Renard, D, 607
- Renfroe, EG, 521
 Ritenbaugh, C, 289, 728
 Rock, CL, 728
 Rodrigues, LC, 540
 Rogers, WJ, 708
 Rowe, PM, 157
 Rubin, RR, 157
- Saano, V, 42
 Saareks, V, 42
 Sampson, AR, 389
 Schneeweiss, S, 757
 Schouten, HJA, 100
 Schron, E, 521
 Schwab, BH, 389
 Scott, NW, 662
 Sébille, V, 423
 Sesso, HD, 686
 Shao, J, 515
 Slocum, W, 554
 Smeeth, L, 409
 Smiell, JM, 389
 Smith, A, 367
 Staten, LK, 289
 Stefanick, ML, 728
 Steffes, M, 708
 Sugarman, J, 222
- Takeuchi, M, 55
 Tardif, JC, 708
 Tavel, JA, 59
 Taylor JMG, 626
 Taylor, T, 333
 Thomas, RG, 728
 Thompson, B, 431
 Thompson, DN, 554
 Thompson, IM, 675
 Thompson, P, 708
 Thomson, C, 728
 Thornquist, MD, 80
 Townes, BD, 301
 Toyoshima, S, 29
 Trivedi, MH, 584
 Tsong, Y, 15
- VA #475 GWVI Antibiotic Treatment Trial Group, 333
- van Raak, L, 74
 VanDenburgh, M, 686
 Verter, JI, 708
 Vining, DJ, 570
- Walley, T, 757
 Wang, PS, 757
 Wang, S-J, 15
 Wang, Y, 626

- Warwick, D, 521
Wasserman, L, 728
Waters, D, 708
Weston, J, 67
WGET Research Group,
 The, 450
Whitehead, J, 422
Wiens, BL, 2
- Williamson, JM, 497
Wise, RA, 87
Wiseman, AL, 333
Women's Healthy
 Eating and Living
 (WHEL) Study
 Group, 728
Woods, JS, 301
- Wright, FA, 728
Yang, P, 429
Yi, Q, 481
Ylitalo, P, 42
Younes, N, 708
Ziemer, DC, 554





Subject Index for Volume 23

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS). *See also HIV INFECTION*

The Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial: rationale, design, and methods of ESPRIT, 198

ACTIVE CONTROLLED TRIALS

Choosing an equivalence limit for noninferiority or equivalence studies, 2
Showing a treatment is good because it is not bad: when does "noninferiority" imply effectiveness?, 52
Utility and pitfalls of some statistical methods in active controlled clinical trials, 15

AFRICAN AMERICANS

The Improving Primary Care of African Americans with Diabetes (IPCAAD) project, 554

ALZHEIMER'S DISEASE

Double placebo design in a prevention trial for Alzheimer's disease, 93
Randomized, placebo-controlled parallel group versus crossover study designs for the study of dementia in Parkinson's disease, 111

ANTIARRHYTHMICS

The end-of-study patient survey: methods influencing response rate in the AVID trial, 521

ANTIRETROVIRAL THERAPY

The dangers of inferring treatment effects from observational data: a case study in HIV infection, 106
The Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial: rationale, design, and methods of ESPRIT, 198

ASSURANCE

Regulatory approvals in a large multinational clinical trial: the ESPRIT experience, 59

ASTHMA

Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics, 87
Quality assurance of asthma clinical trials, 143

BACILLUS CALMETTE-GUERIN (BCG)

Design of the Brazilian BCG-REVAG trial against tuberculosis: a large, simple randomized community trial to evaluate the impact on tuberculosis of BCG revaccination at school age, 540

BIAS

Bias in a placebo-controlled study due to mismeasurement of disease status and the regression effect, 497
The dangers of inferring treatment effects from observational data: a case study in HIV infection, 106
Randomized, placebo-controlled parallel group versus crossover study designs for the study of dementia in Parkinson's disease, 111

BIOMARKERS

Biomarker-based methods for determining noncompliance in a prevention trial, 675
Surrogate markers and joint models for longitudinal and survival data, 626

BIVARIATE STUDY DESIGN

The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes, 240

BONE MARROW TRANSPLANT

The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes, 240

BOOK REVIEWS

- Analyzing Medical Data Using S-PLUS*, 429
- Biostatistics in Clinical Trials*, 536
- Statistical Aspects of the Design and Analysis of Clinical Trials*, 299
- The Truth About Hormone Replacement Therapy: How to Break Free from the Medical Myths of Menopause*, 537

CANCER. See CANCER PREVENTION; PROSTATE CANCER**CANCER PREVENTION**

- Biomarker-based methods for determining noncompliance in a prevention trial, 675
- Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians Health Study, 686
- A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study, 728
- Some design issues in a community intervention trial, 431
- The Virtual Colonoscopy Study: a large multicenter clinical trial designed to compare two diagnostic screening procedures, 570

CARDIOVASCULAR DISEASE

- Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians Health Study, 686
- The end-of-study patient survey: methods influencing response rate in the AVID trial, 521
- Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial, 757
- Women's Angiographic Vitamin and Estrogen trial: design and methods, 708

CLUSTER RANDOMIZATION

- Design of the Brazilian BCG-REVAG trial against tuberculosis: a large, simple randomized community trial to evaluate the impact on tuberculosis of BCG revaccination at school age, 540
- Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community, 409
- Some design issues in a community intervention trial, 431

COLONOSCOPY

- The Virtual Colonoscopy Study: a large multicenter clinical trial designed to compare two diagnostic screening procedures, 570

COMPOSITE ENDPOINTS

- Improving the information content of categorical clinical trial endpoints, 502

COMPUTERS

- The use of handheld computers in clinical trials, 469

CONSENT FORMS. See INFORMED CONSENT**CONSORT STATEMENT**

- The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist, 380

CONTINUAL REASSESSMENT METHOD (CRM)

- The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes, 240

COVARIATE ADJUSTMENT

- On the variability of covariate adjustment: experience with Koch's method for evaluating the absolute difference in proportions in randomized clinical trials, 127

CROSSOVER

- Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics, 87
 Randomized, placebo-controlled parallel group versus crossover study designs for the study of dementia in Parkinson's disease, 111
 Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint, 650

DEMENTIA. *See ALZHEIMER'S DISEASE***DENTAL AMALGAM**

- Issues in design and analysis of a randomized clinical trial to assess the safety of dental amalgam restorations in children, 301

DEPRESSION

- The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression, 584

DESIGN PAPERS

- The Antibiotic Treatment Trial of Gulf War Veterans' Illnesses: issues, design, screening, and baseline characteristics, 333
 Design of the Brazilian BCG-REVAG trial against tuberculosis: a large, simple randomized community trial to evaluate the impact on tuberculosis of BCG revaccination at school age, 540
 Design of the Wegener's Granulomatosis Etanercept Trial (WGET), 450
 The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression, 584
 The Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial: rationale, design, and methods of ESPRIT, 198
 The Improving Primary Care of African Americans with Diabetes (IPCAAD) project, 554
 Issues in design and analysis of a randomized clinical trial to assess the safety of dental amalgam restorations in children, 301
 Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic

analysis components of the PROSPER trial, 757

- A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study, 728
 Research on informed consent: investigator-developed versus focus group-developed consent documents, a VA cooperative study, 184
 Some design issues in a community intervention trial, 431
 The Virtual Colonoscopy Study: a large multicenter clinical trial designed to compare two diagnostic screening procedures, 570
 Women's Angiographic Vitamin and Estrogen trial: design and methods, 708

DIABETES

- The Diabetes Prevention Program: recruitment methods and results, 157
 The Improving Primary Care of African Americans with Diabetes (IPCAAD) project, 554

DIET

- A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study, 728

DNA BANKING

- Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study, 222

DRUG DEVELOPMENT/APPROVAL

- The issues to be considered in global drug development, 55
 A meta-analytic approach to an integrated summary of efficacy: a case study of bcaplermin gel, 389
 The quality and characteristics of clinical drug study notifications reviewed by the regulatory agency in Finland, 42

DRUG MASKING

- Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics, 87

DYSPEPSIA

A placebo-controlled randomized trial of eradication of *Helicobacter pylori* in the general population: study design and response rates of the Bristol Helicobacter Project, 321

ELDERLY

Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community, 409

Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial, 757

EQUIVALENCE

Choosing an equivalence limit for noninferiority or equivalence studies, 2

A note on statistical methods for assessing therapeutic equivalence, 515

Showing a treatment is good because it is not bad: when does "noninferiority" imply effectiveness?, 52

Utility and pitfalls of some statistical methods in active controlled clinical trials, 15

ESTROGEN

Women's Angiographic Vitamin and Estrogen trial: design and methods, 708

ETANERCEPT

Design of the Wegener's Granulomatosis Etanercept Trial (WGET), 450

ETHICS

The ethics of research on informed consent, 172

Implementing the EGASIS trial, an international multicenter acute intervention trial in stroke, 74

Making informed consent meaningful: from theory to practice, 178

Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study, 222

Prospective preference assessment: a method to enhance the ethics and

efficiency of randomized control trials, 274

Regulatory approvals in a large multinational clinical trial: the ESPRIT experience, 59

EXERCISE

The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression, 584

FDA. See DRUG DEVELOPMENT/APPROVAL

FOCUS GROUPS

Making informed consent meaningful: from theory to practice, 178

Research on informed consent: investigator-developed versus focus group-developed consent documents, a VA cooperative study, 184

FUNDING

Implementing the EGASIS trial, an international multicenter acute intervention trial in stroke, 74

FUTILITY MONITORING

A comment on futility monitoring, 355

GOOD CLINICAL PRACTICE

The issues to be considered in global drug development, 55

The quality and characteristics of clinical drug study notifications reviewed by the regulatory agency in Finland, 42

The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections, 29

GULF WAR VETERANS' ILLNESSES

The Antibiotic Treatment Trial of Gulf War Veterans' Illnesses: issues, design, screening, and baseline characteristics, 333

The ethics of research on informed consent, 172

Making informed consent meaningful: from theory to practice, 178

Research on informed consent: investigator-developed versus focus group-developed consent documents, a VA cooperative study, 184

HEALTH CARE ACCESS

Recruitment of Hispanic women to the Women's Health Initiative: the case of *Embajadoras* in Arizona, 289

HELICOBACTER PYLORI

A placebo-controlled randomized trial of eradication of *Helicobacter pylori* in the general population: study design and response rates of the Bristol Helicobacter Project, 321

HISPANIC AMERICANS

Recruitment of Hispanic women to the Women's Health Initiative: the case of *Embajadoras* in Arizona, 289
Some design issues in a community intervention trial, 431

HIV INFECTION

The dangers of inferring treatment effects from observational data: a case study in HIV infection, 106
The Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial: rationale, design, and methods of ESPRIT, 198

HORMONE REPLACEMENT THERAPY

Women's Angiographic Vitamin and Estrogen trial: design and methods, 708

HOSPITAL AUDITS

The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections, 29

HUMAN SUBJECT REVIEW

Regulatory approvals in a large multinational clinical trial: the ESPRIT experience, 59

Streamlining IRB review in multisite trials through single-study IRB cooperative agreements: experience of the β -Carotene and retinol efficacy trial (CARET), 80

IMPAIRED GLUCOSE TOLERANCE (IGT). See DIABETES**INFLUENZA**

Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics, 87

INFORMED CONSENT

The ethics of research on informed consent, 172

Implementing the EGASIS trial, an international multicenter acute intervention trial in stroke, 74

Making informed consent meaningful: from theory to practice, 178

Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study, 222

Regulatory approvals in a large multinational clinical trial: the ESPRIT experience, 59

Research on informed consent: investigator-developed versus focus group-developed consent documents, a VA cooperative study, 184

INSTITUTIONAL REVIEW BOARDS (IRBs)

The ethics of research on informed consent, 172

Making informed consent meaningful: from theory to practice, 178

Regulatory approvals in a large multinational clinical trial: the ESPRIT experience, 59

Streamlining IRB review in multisite trials through single-study IRB cooperative agreements: experience of the β -Carotene and retinol efficacy trial (CARET), 80

INTERLEUKIN-2

The Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial: rationale, design, and methods of ESPRIT, 198

INTERNATIONAL COLLABORATION

Crossing international boundaries: implications for the Term Breech Trial Data Coordinating Centre, 67

The Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial: rationale, design, and methods of ESPRIT, 198

Regulatory approvals in a large multinational clinical trial: the ESPRIT experience, 59

INTRACLASS CORRELATION COEFFICIENT

Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community, 409

LANCASTER DECOMPOSITION

Improving the information content of categorical clinical trial endpoints, 502

LAY ADVOCATES

Recruitment of Hispanic women to the Women's Health Initiative: the case of *Embajadoras* in Arizona, 289

MERCURY TOXICITY

Issues in design and analysis of a randomized clinical trial to assess the safety of dental amalgam restorations in children, 301

META-ANALYSIS

A meta-analytic approach to an integrated summary of efficacy: a case study of becaplermin gel, 389
Statistical challenges in the evaluation of surrogate endpoints in randomized trials, 607

MINIMIZATION

The method of minimization for allocation to clinical trials: a review, 662

MISCLASSIFICATION

Bias in a placebo-controlled study due to mismeasurement of disease status and the regression effect, 497

MIXED MODELS

Estimating sample size for tests on trends across repeated measurements with missing data based on the interaction term in a mixed model, 481

MONITORING GUIDELINES

A comment on futility monitoring, 355

NEUROLOGICAL DISEASE. See also ALZHEIMER'S DISEASE

Design and analysis of two-period studies of potentially disease modifying treatments, 635

NONCOMPLIANCE

Biomarker-based methods for determining noncompliance in a prevention trial, 675

NONINFERIORITY

Choosing an equivalence limit for noninferiority or equivalence studies, 2

On the variability of covariate adjustment: experience with Koch's method for evaluating the absolute difference in proportions in randomized clinical trials, 127

Showing a treatment is good because it is not bad: when does "noninferiority" imply effectiveness?, 52

Utility and pitfalls of some statistical methods in active controlled clinical trials, 15

The Virtual Colonoscopy Study: a large multicenter clinical trial designed to compare two diagnostic screening procedures, 570

OBSERVATIONAL STUDY

The dangers of inferring treatment effects from observational data: a case study in HIV infection, 106

PALMPILOT PDAs

The use of handheld computers in clinical trials, 469

PARKINSON'S DISEASE

Design and analysis of two-period studies of potentially disease modifying treatments, 635

Randomized, placebo-controlled parallel group versus crossover study designs for the study of dementia in Parkinson's disease, 111

PARTICIPANT PREFERENCES

Prospective preference assessment: a method to enhance the ethics and efficiency of randomized control trials, 274

PATIENT SURVEYS

The end-of-study patient survey: methods influencing response rate in the AVID trial, 521

PHARMACOGENETICS

Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study, 222

PHASE II DESIGN

An optimal two-stage phase II design utilizing the complete and partial response information separately, 367

PILL COUNTS

Biomarker-based methods for determining noncompliance in a prevention trial, 675

PLACEBO

Bias in a placebo-controlled study due to mismeasurement of disease status and the regression effect, 497

Design of the Wegener's Granulomatosis Etanercept Trial (WGET), 450

Double placebo design in a prevention trial for Alzheimer's disease, 93

Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics, 87

A placebo-controlled randomized trial of eradication of *Helicobacter pylori* in the general population: study design and response rates of the Bristol Helicobacter Project, 321

Randomized, placebo-controlled parallel group versus crossover study designs for the study of dementia in Parkinson's disease, 111

Utility and pitfalls of some statistical methods in active controlled clinical trials, 15

Women's Angiographic Vitamin and Estrogen trial: design and methods, 708

POWER

A comment on futility monitoring, 355

Estimating sample size for tests on trends across repeated measurements with missing data based on the interaction term in a mixed model, 481

Guidelines for the design of clinical trials with longitudinal outcomes, 257

Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community, 409

PRAVASTATIN

Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial, 757

PRESERVATION OF CONTROL**EFFECT**

Choosing an equivalence limit for noninferiority or equivalence studies, 2

A note on statistical methods for assessing therapeutic equivalence, 515

Showing a treatment is good because it is not bad: when does "noninferiority" imply effectiveness?, 52

Utility and pitfalls of some statistical methods in active controlled clinical trials, 15

PREVENTION. See also CANCER PREVENTION

Double placebo design in a prevention trial for Alzheimer's disease, 93

PROSTATE CANCER

Biomarker-based methods for determining noncompliance in a prevention trial, 675

PROVIDER ADHERENCE

The Improving Primary Care of African Americans with Diabetes (IPCAAD) project, 554

QUALITY CONTROL

Quality assurance of asthma clinical trials, 143

The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist, 380

RECRUITMENT

- Crossing international boundaries: implications for the Term Breech Trial Data Coordinating Centre, 67
 The Diabetes Prevention Program: recruitment methods and results, 157
 Prospective preference assessment: a method to enhance the ethics and efficiency of randomized control trials, 274
 Recruitment of Hispanic women to the Women's Health Initiative: the case of *Embajadoras* in Arizona, 289

REGULATORY REQUIREMENTS

- The quality and characteristics of clinical drug study notifications reviewed by the regulatory agency in Finland, 42
 Regulatory approvals in a large multinational clinical trial: the ESPRIT experience, 59

REPEATED MEASUREMENTS

- Estimating sample size for tests on trends across repeated measurements with missing data based on the interaction term in a mixed model, 481

RUN-IN

- Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians Health Study, 686

SAFETY

- The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression, 584
 Issues in design and analysis of a randomized clinical trial to assess the safety of dental amalgam restorations in children, 301

SAMPLE SIZE

- Estimating sample size for tests on trends across repeated measurements with missing data based on the interaction term in a mixed model, 481
 Guidelines for the design of clinical trials with longitudinal outcomes, 257

Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community, 409

Issues in design and analysis of a randomized clinical trial to assess the safety of dental amalgam restorations in children, 301

Prospective preference assessment: a method to enhance the ethics and efficiency of randomized control trials, 274

Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint, 650

SMOKING CESSATION

- Some design issues in a community intervention trial, 431

SPIROMETRY

- Quality assurance of asthma clinical trials, 143

STROKE

Implementing the EGASIS trial, an international multicenter acute intervention trial in stroke, 74

Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial, 757

SUPERIORITY

On the variability of covariate adjustment: experience with Koch's method for evaluating the absolute difference in proportions in randomized clinical trials, 127

SURROGATE ENDPOINTS

Evaluating surrogate endpoints, 703
 Statistical challenges in the evaluation of surrogate endpoints in randomized trials, 607

Surrogate markers and joint models for longitudinal and survival data, 626

SYSTEMIC VASCULITIS

Design of the Wegener's Granulomatosis Etanercept Trial (WGET), 450

TREATMENT ALLOCATION

The method of minimization for allocation to clinical trials: a review, 662

TRIAL MANAGEMENT

Crossing international boundaries: implications for the Term Breech Trial Data Coordinating Centre, 67

Design of the Wegener's Granulomatosis Etanercept Trial (WGET), 450

Implementing the EGASIS trial, an international multicenter acute intervention trial in stroke, 74

Prospective preference assessment: a method to enhance the ethics and efficiency of randomized control trials, 274

TRINOMIAL MODEL

An optimal two-stage phase II design utilizing the complete and partial response information separately, 367

TUBERCULOSIS

Design of the Brazilian BCG-REVAG trial against tuberculosis: a large, simple randomized community trial to evaluate the impact on tuberculosis of BCG revaccination at school age, 540

TUMOR NECROSIS FACTOR

Design of the Wegener's Granulomatosis Etanercept Trial (WGET), 450

TWO ONE-SIDED TESTS (TOST) APPROACH

A note on statistical methods for assessing therapeutic equivalence, 515

ULCER THERAPY

A meta-analytic approach to an integrated summary of efficacy: a case study of becaplermin gel, 389

VACCINATION

Design of the Brazilian BCG-REVAG trial against tuberculosis: a large, simple randomized community trial to evaluate the impact on tuberculosis of BCG revaccination at school age, 540

Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics, 87

WEGENER'S GRANULOMATOSIS

Design of the Wegener's Granulomatosis Etanercept Trial (WGET), 450

WOMEN'S HEALTH

A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study, 728

Recruitment of Hispanic women to the Women's Health Initiative: the case of *Embajadoras* in Arizona, 289

Women's Angiographic Vitamin and Estrogen trial: design and methods, 708